Bedaquiline: a review of human pharmacokinetics and drug-drug interactions

Bedaquiline has recently been approved for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. It is metabolized primarily by the cytochrome P450 isoenzyme 3A4 (CYP3A4) to a less-active N-monodesmethyl metabolite. Phase I and Phase II studies in...

Celý popis

Podrobná bibliografia

Vydané v:	Journal of antimicrobial chemotherapy Ročník 69; číslo 9; s. 2310
Hlavní autori:	van Heeswijk, R P G, Dannemann, B, Hoetelmans, R M W
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 01.09.2014
Predmet:	Antifungal Agents - pharmacology Antitubercular Agents - pharmacokinetics Antitubercular Agents - pharmacology Antiviral Agents - pharmacology Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Diarylquinolines - pharmacokinetics Diarylquinolines - pharmacology Drug Interactions Humans Tuberculosis, Multidrug-Resistant - drug therapy CYP3A clinical trials HIV tuberculosis
ISSN:	1460-2091, 1460-2091
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!